Descriptions of health states associated with increasing severity and frequency of hypoglycemia: A patient-level perspective

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 925-936

  Harris, Stewart B ^a   Khunti, Kamlesh ^b   Landin Olsson, Mona ^c   Galbo Jørgensen, Claus B ^d   Bøgelund, Mette ^d   Chubb, Barrie ^e   Gundgaard, Jens ^f   Evans, Marc ^g  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c LUND UNIVERSITY   (Sweden)

^d Holte Stationsvej 14   (Denmark)

^e Novo Nordisk Ltd   (United Kingdom)

^f NOVO NORDISK A S   (Denmark)

^g LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Diabetes; Health states; Hypoglycemia; Quality of life

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH STATUS; HUMAN; HYPOGLYCEMIA; LIFE EVENT; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PATIENT ATTITUDE; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; SOCIAL PSYCHOLOGY; SYMPTOM ASSESSMENT;

EID: 84884400533     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S46805     Document Type: Article

References (35)

1. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on diabetes management and work productivity. Value Health. 2011;14(5):665-671.
2. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
3. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001;161(13):1653-1659.
4. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140-1147.
5. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab. 2008;10 Suppl 1:16-24.
6. Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002;25(10):1737-1743.
7. Zoungas S, Patel A, Chalmers J, et al; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410-1418.
8. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-1395.
9. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med. 2005;22(6):749-755.
10. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008;10 Suppl 1:25-32.
11. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20(12):1016-1021.
12. Lammert M, Hammer M, Frier BM. Management of severe hypoglycemia: cultural similarities, differences and resource consumption in three European countries. J Med Econ. 2009;12(4):269-280.
13. Barendse S, Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review. Diabet Med. 2012;29(3):293-302.
14. Frier BM. How hypoglycemia can affect the life of a person with diabetes. Diabetes Metab Res Rev. 2008;24(2):87-92.
15. Graveling AJ, Frier BM. Hypoglycaemia: an overview. Prim Care Diabetes. 2009;3(3):131-139.
16. Leiter LA, Yale J-F, Chiasson J-L, Harris S, Kleinstiver P, Luc Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diab. 2005;29(3):186-192.
17. Marrett E, Stargardt T, Mavros P, Alexander CM. Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes Obes Metab. 2009;11(12):1138-1144.
18. Nafees B, Lloyd A, Kennedy-Martin T, Hynd S. How diabetes and insulin therapy affects the lives of people with type 1 diabetes. Eur Diabetes Nurs. 2006;3(1):92-97.
19. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682-689.
20. Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns. 2007;68(1):10-15.
21. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011;91(3):363-370.
22. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002;45(7): 937-948.
23. Unger J. Uncovering undetected hypoglycemic events. Diabetes Metab Syndr Obes. 2012;5:57-74.
24. Kilpatrick ES, Das AK, Orskov C, Berntorp K. Good glycaemic control: an international perspective on bridging the gap between theory and practice in type 2 diabetes. Curr Med Res Opin. 2008;24(9):2651-2661.
25. Alvarez-Guisasola F, Yin DD, Nocea G, Qiu Y, Mavros P. Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study. Health Qual Life Outcomes. 2010;8:86.
26. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin. 2005;21(9):1477-1483.
27. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007;16(7): 1251-1265.
28. Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11(1):90. [Epub ahead of print.]
29. Szende A, Brazier J, Schaefer C, Deuson R, Isitt JJ, Vyas P. Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura. Curr Med Res Opin. 2010;26(8):1893-1903.
30. Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, Prosser LA. Willingness to pay for a QUALY based on community member and patient preferences for temporary health states associated with herpes zoster. Pharmacoeconomics. 2009;27(12):1005-1016.
31. Chang WT, Collins ED, Kerrigan CL. An Internet-based utility assessment of breast hypertrophy. Plast Reconstr Surg. 2001;108(2):370-377.
32. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53-72.
33. Dolan P. Modeling valuations for EuroQol health states. Med Care.1997;35(11):1095-1108.
34. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
35. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523-1534.